Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening
2024年5月23日 - 8:05PM
ビジネスワイヤ(英語)
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology
company, today announced that Nasdaq has temporarily halted trading
of the company's stock.
The Molecular and Clinical Genetics Panel of the U.S. Food and
Drug Administration (FDA) Medical Devices Advisory Committee will
meet today to review the premarket approval (PMA) application for
ShieldTM, Guardant Health’s blood test to screen for colorectal
cancer in average-risk adults.
The panel meeting is scheduled to begin at 9:30 a.m. ET.
FDA advisory committees provide independent expert advice and
non-binding recommendations to the FDA on certain products to help
the agency make sound decisions based on the available science.
About Guardant Health
Guardant Health is a leading precision oncology company focused
on guarding wellness and giving every person more time free from
cancer. Founded in 2012, Guardant is transforming patient care by
providing critical insights into what drives disease through its
advanced blood and tissue tests, real-world data and AI analytics.
Guardant tests help improve outcomes across all stages of care,
including screening to find cancer early, monitoring for recurrence
in early-stage cancer, and helping doctors select the best
treatment for patients with advanced cancer. For more information,
visit guardanthealth.com and follow the company on LinkedIn, X
(Twitter) and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240523721275/en/
Investors: Zarak Khurshid
investors@guardanthealth.com
Media: Mike Weist press@guardanthealth.com +1
650-647-3643
Guardant Health (NASDAQ:GH)
過去 株価チャート
から 5 2024 まで 6 2024
Guardant Health (NASDAQ:GH)
過去 株価チャート
から 6 2023 まで 6 2024